

**CA OPIOID SETTLEMENTS**  
**EXPENDITURE REPORTING FORM**

**SFY 2023 - 2024**

**Prepared on 2025-12-04 by the University of  
California, Los Angeles**

**Integrated Substance Use and Addictions Programs**



# CONTENTS

GENERAL INFORMATION	1
CA ABATEMENT ACCOUNT FUNDS INFORMATION	1
CA Abatement Payments: . . . . .	1
CA Abatement Reallocations: . . . . .	2
CA Abatement Expenditures: . . . . .	2
Activity#1 . . . . .	2
Activity#2 . . . . .	3
CA SUBDIVISION FUND INFORMATION	4
MALLINCKRODT BANKRUPTCY (NOAT II) FUND INFORMATION	5
Mallinckrodt Bankruptcy Payments: . . . . .	5
Mallinckrodt Reallocations: . . . . .	5
Mallinckrodt Allowable Expenses: . . . . .	5
SUMMARY	6

# GENERAL INFORMATION

**Participating Subdivision:** Gilroy City  
**Subdivision Department/Organization:** Administration  
**Subdivision address:** 7351 Rosanna Street Gilroy CA 95020  
**Name of Preparer:** Bryce Atkins  
**Preparer Title:** Assistant to the City Administrator  
**Preparer Email Address:** bryce.atkins@cityofgilroy.org  
**Preparer Phone Number:** 4088460210  
**This Subdivision received funds from:**  
Settlements & Mallinckrodt Pharmaceuticals Bankruptcy

# CA ABATEMENT ACCOUNT FUNDS INFORMATION

- Settlement(s):**
- Distributors (McKesson, Cardinal Health and Cencora, previously Amerisource Bergen)
  - Janssen Pharmaceuticals, Inc.

## CA Abatement Payments:

Payments Received by this Subdivision from the CA Abatement Account Fund

Settlement	CA Abatement Account Payments Received in SFY 23-24
Distributors	\$18,757.61
Janssen	\$8,474.51

---

**Is your Participating Subdivision depositing CA Abatement Accounts Fund payments from the National Settlement Administrator (Brown-Greer, PLC) into an interest-bearing account?:** Yes

Interest Earned from the CA Abatement Account Fund

Settlement	CA Abatement Account Interest Earned in SFY 23-24
Distributors	\$500.83
Janssen	\$308.72

### CA Abatement Reallocations:

**Reallocations Sent:** No funds received from the CA Abatement Account were reallocated to another Subdivision.

**Reallocations Received:** No funds received from the CA Abatement Account were reallocated from another Subdivision.

### CA Abatement Expenditures:

**How many total activities or programs funded by the funds from the CA Abatement Accounts Fund will you be reporting on for the SFY 23-24 (period of July 1, 2023 - June 30, 2024)?:** 2

#### Activity#1

**Activity or Program Name:** Naloxone Purchase

**Activity or Program Description:** The City of Gilroy purchased 500 units of naloxone in May of 2024 to distribute to City employees in Public Works and Police Departments to have with them should they encounter members of the public needing the administration of this life saving medicine.

Activity Costs and Encumbered Funds

Settlement	Direct Costs in SFY 23-24	Indirect Costs (Admin. Expenses) in SFY 23-24	Funds Encumbered in SFY 23-24
Distributors	\$15,239.11	\$0.00	\$0.00
Janssen	\$8,047.68	\$0.00	\$0.00

**Did you previously encumber funds for this activity in SFY 22-23 that were not expended in SFY 23-24?:** No

**Activity Start Date (mm/dd/yyyy):** 05/01/2024

**All local agencies or organizations who were given funds during SFY 23-24 to implement this activity:**

Internal only - City of Gilroy

**Allowable Expenditure Category:** Prevent Overdose Deaths and Other Harms (Harm Reduction)

High Impact Abatement Activity (HIAA) Category

HIAA Satisfied	Reasoning
<b>HIAA 6:</b> The purchase of naloxone for distribution and efforts to expand access to naloxone for opioid overdose reversals Please describe:	The entire amount went to the purchase of naloxone for use in the community by City staff if the need arises.

**Activity#2**

**Activity or Program Name:** Fentanyl Kills Campaign

**Activity or Program Description:** This program involved the payment for Facebook “pushes” of the City’s social media campaign to raise awareness of the dangers of Fentanyl.

Activity Costs and Encumbered Funds

Settlement	Direct Costs in SFY 23-24	Indirect Costs (Admin. Expenses) in SFY 23-24	Funds Encumbered in SFY 23-24
Distributors	\$239.06	\$0.00	\$0.00
Janssen	\$147.36	\$0.00	\$0.00

**Did you previously encumber funds for this activity in SFY 22-23 that were not expended in SFY 23-24?:** No

**Activity Start Date (mm/dd/yyyy):** 10/01/2023

**All local agencies or organizations who were given funds during SFY 23-24 to implement this activity:**

None - Internal Only

**Allowable Expenditure Category:** Prevent Misuse of Opioids

This activity does not meet the criteria to be a High Impact Abatement Activity.

## CA SUBDIVISION FUND INFORMATION

**Is your Participating Subdivision also a Plaintiff Subdivision?:** No

# MALLINCKRODT BANKRUPTCY (NOAT II) FUND INFORMATION

**Did your Local Government receive funds from the Mallinckrodt Bankruptcy (NOAT II)?:** Yes

## Mallinckrodt Bankruptcy Payments:

**Total amount of funds received from NOAT II from July 1, 2023 – June 30, 2024:**

\$2,616.81

**Is your Local Government depositing Mallinckrodt Bankruptcy payments from NOAT II into an interest-bearing account?**

Yes

**Total amount of Interest earned from NOAT II from July 1, 2023 – June 30, 2024:**

\$60.93

## Mallinckrodt Reallocations:

### Reallocations Sent:

No funds received from the Mallinckrodt Bankruptcy Funds were reallocated to another Subdivision.

### Reallocations Received:

No funds received from the Mallinckrodt Bankruptcy Funds were reallocated from another Subdivision.

## Mallinckrodt Allowable Expenses:

**Did your Local Government expend any bankruptcy funds during the period of July 1, 2023 – June 30, 2024?:** Yes

## Mallinckrodt Allowable Expenses Breakdown

Approved Category	Direct Costs July - Dec. 2023	Direct Costs Jan. - June 2024	Indirect Costs July - Dec. 2023	Indirect Costs Jan - June 2024
Schedule A.A. Naloxone or Other FDA-Approved Drug to Reverse Opioid Overdoses	\$0.00	\$1,588.21	\$0.00	\$0.00
Schedule B.G. Prevent Misuse of Opioids	\$13.59	\$0.00	\$0.00	\$0.00

## SUMMARY

**All tables below are based on information reported during the SFY 2023-24 only.**

### CA Abatement Account Fund Totals

Settlement	Payment	Interest	Reallocations Sent	Reallocations Received
Distributors	\$18,757.61	\$500.83	\$0.00	\$0.00
Janssen	\$8,474.51	\$308.72	\$0.00	\$0.00
Total	\$27,232.12	\$809.55	\$0.00	\$0.00

CA Abatement Account Activity Expenses

<b>Settlement</b>	<b>Activity Expenses</b>	<b>Indirect Costs</b>	<b>23/24 Encumbered Funds</b>	<b>22/23 Encumbered Funds</b>
Distributors	\$15,478.17	\$0.00	\$0.00	\$0.00
Janssen	\$8,195.04	\$0.00	\$0.00	\$0.00
Total	\$23,673.21	\$0.00	\$0.00	\$0.00

Mallinckrodt Bankruptcy (NOAT II) Fund Totals

<b>Payment</b>	<b>Interest</b>	<b>Reallocations Sent</b>	<b>Reallocations Received</b>
\$2,616.81	\$60.93	\$0.00	\$0.00

Mallinckrodt Bankruptcy (NOAT II) Fund Expenses

<b>Direct Costs</b>	<b>Indirect Costs</b>
\$1,601.80	\$0.00